Published in final edited form as:

Breast Cancer Res Treat. 2009 July ; 116(2): 379–386. doi:10.1007/s10549-008-0153-8.

***BRCA1* and *BRCA2* mutation carriers in the Breast Cancer Family Registry: an open resource for collaborative research**

Susan L. Neuhausen,

Department of Epidemiology, University of California Irvine, Irvine, CA 92697-7550, USA

Hilmi Ozcelik,

Division of Epidemiology and Biostatistics, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, ON, Canada

Melissa C. Southey,

Department of Pathology, The University of Melbourne, Parkville, VIC, Australia

Esther M. John,

Northern California Cancer Center, Fremont, CA, USA

Andrew K. Godwin,

Fox Chase Cancer Center, Philadelphia, PA, USA

Wendy Chung,

Department of Pediatrics and Medicine, Columbia University, New York, NY, USA

Jeniffer Iriondo-Perez,

Research Triangle Institute, Raleigh, NC, USA

Alexander Miron,

Department of Cancer Biology, Dana Farber Cancer Center, Boston, MA, USA

Regina M. Santella,

Mailman School of Public Health, Columbia University, New York, NY, USA

Alice Whittemore,

Stanford University School of Medicine, Palo Alto, CA, USA

Irene L. Andrulis,

Ontario Cancer Genetics Network, Cancer Care Ontario, Fred A. Litwin Center for Cancer Genetics, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, ON, Canada

Sandra S. Buys,

Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT, USA

Mary B. Daly,

Fox Chase Cancer Center, Philadelphia, PA, USA

John L. Hopper,

Center for Molecular, Environmental, Genetic and Analytic Epidemiology, The University of Melbourne, Parkville, VIC, Australia

Daniela Seminara,

Epidemiology and Genetics Research Program, Clinical and Genetic Epidemiology Research Branch, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD, USA

Ruby T. Senie,

Mailman School of Public Health, Columbia University, New York, NY, USA

Mary Beth Terry, and

Mailman School of Public Health, Columbia University, New York, NY, USA

Bethesda, USA

Breast Cancer Family Registry

Susan L. Neuhausen: sneuhaus@uci.edu; Hilmi Ozelik; ; Melissa C. Southey; ; Esther M. John; ; Andrew K. Godwin; ; Wendy Chung; ; Jeniffer Iriondo-Perez; ; Alexander Miron; ; Regina M. Santella; ; Alice Whittemore; ; Irene L. Andrulis; ; Sandra S. Buys; ; Mary B. Daly; ; John L. Hopper; ; Daniela Seminara; ; Ruby T. Senie; ; Mary Beth Terry; ;

Abstract

The Breast Cancer Family Registry is a resource for interdisciplinary and translational studies of the genetic epidemiology of breast cancer. This resource is available to researchers worldwide for collaborative studies. Herein, we report the results of testing for germline mutations in *BRCA1* and *BRCA2*. We have tested 4,531 probands for mutations in *BRCA1* and 4,084 in *BRCA2*. Deleterious mutations in *BRCA1* and *BRCA2* were identified for 9.8% of probands tested [233/4,531 (5.1%) for *BRCA1* and 193/4,084 (4.7%) for *BRCA2*]. Of 1,385 Ashkenazi Jewish women tested for only the three founder mutations, 17.4% carried a deleterious mutation. In total, from the proband and subsequent family testing, 1,360 female mutation carriers (788 in *BRCA1*, 566 in *BRCA2*, 6 in both *BRCA1* and *BRCA2*) have been identified. The value of the resource has been greatly enhanced by determining the germline *BRCA1* and *BRCA2* mutation statuses of nearly 6,000 probands.

Keywords

Biospecimen repository; Breast cancer; *BRCA1*; *BRCA2*

Introduction

The Breast Cancer Family Registry (Breast CFR), composed of six international registries and collaborating institutions, was established by the National Cancer Institute (USA) in 1995 to create a resource to facilitate collaborative interdisciplinary and translational studies of the genetic epidemiology of breast cancer [1]. The Breast CFR is available to researchers worldwide for collaborative studies (<http://epi.grants.cancer.gov/CFR/>). Over 40,000 participants from more than 13,000 families have been enrolled. These include incident breast cancer cases and their relatives ascertained through population-based cancer registries (population-based case families), families with strong cancer histories identified through cancer family clinics and community outreach (clinic-based families), and unaffected women and their relatives sampled from the populations (population-based control families). In addition, there was a specific recruitment of Ashkenazi Jewish women with a personal and/or family history of breast cancer. Population-based families were recruited from the San Francisco Bay area, California (California Breast CFR), the Province of Ontario, Canada (Ontario Breast CFR); and Melbourne and Sydney, Australia (Australian Breast CFR). Clinic-based families were recruited from Philadelphia (Philadelphia Breast CFR), New York City (New York Breast CFR), Utah (Utah Breast CFR), Ontario, Canada (Ontario Breast CFR), and Melbourne and Sydney, Australia (Australian Breast CFR). Specific recruitment of Ashkenazi-Jewish families was conducted by the New York, Philadelphia, Ontario and Australian Breast CFRs. All registries used the Breast CFR's standardized questionnaires and protocols to collect

family history information, epidemiological and clinical data, and biological specimens (blood and/or buccal samples and tumor tissue), with quality control measures throughout the collection, processing, and storing of data and samples. Families are continuing to be followed for new cancer diagnoses and treatment and disease-free survival for breast cancer cases.

Information on the germline *BRCA1* and/or *BRCA2* mutation status of individuals is needed for many research projects that use the Breast CFR. For example, some studies specifically require mutation carriers only, other studies exclude these carriers as far as is possible, while other studies compare specific characteristics of carriers with those of non-carriers. To facilitate these endeavors, we report the results of a collaborative study through the Breast CFR to identify *BRCA1* and *BRCA2* mutation carriers.

Materials and methods

Subjects

Details of the enrollment criteria were previously described in detail [1]. In brief, the enrollment criteria were as follows:

- a. *Population-based families* The California Breast CFR recruited population-based case probands younger than 65 years at diagnosis through the SEER cancer registry of the Greater San Francisco Bay area. A two-stage sampling scheme was used with an over-sampling based on age at diagnosis and cancer family history. More recently, recruitment has been limited to African-American and Hispanic breast cancer cases. The Ontario Breast CFR recruited population-based case probands diagnosed before the age of 70 years using a two-stage sampling scheme, with over-sampling based on age at diagnosis and cancer family history, through the Ontario Cancer Registry, a voluntary cancer registry that includes 98% of breast cancer cases diagnosed in Ontario. The Australian Breast CFR recruited case probands, stratified by age at diagnosis and unselected for family history, through the Victorian and New South Wales Cancer Registries, for which registration of all cases is mandated by law. Unaffected women were sampled from the population-based sites to be used as populationbased control families. The Australian Breast CFR also enrolled family members of control probands. No mutation testing for control probands is described in this paper.
- b. *Clinic-based multiple-case families* The Philadelphia Breast CFR recruited affected probands with a family history of breast and/or ovarian cancer from the Fox Chase Network of community hospitals, and Cooper Hospital/University Medical Center in Camden New Jersey, and unaffected probands with a family history of breast cancer from the Family Risk Assessment Programs (FRAP) at these institutions. The New York Breast CFR similarly recruited affected and unaffected probands with a family history of breast and/or ovarian cancer from hospitals and through community-based outreach to local organizations and breast cancer support groups. The Utah Breast CFR recruited families with three or more cases of breast or ovarian cancer, especially if at least one of the cancers occurred before the age of 45 years, from local clinicians, the Family Cancer Assessment Clinic at Huntsman Cancer Institute, and another ongoing research study. The Australian Breast CFR recruited affected and unaffected probands with at least two affected relatives through cancer family clinics in Victoria and New South Wales, and through physician referral.
- c. *Ashkenazi-Jewish families* The New York, Philadelphia, Ontario and Australian Breast CFRs recruited Ashkenazi-Jewish women, predominantly those with a personal or family history of breast cancer, through clinics and the local communities [2].

***BRCA1* and *BRCA2* mutation testing**

Testing for *BRCA1* and *BRCA2* mutations was not supported as part of the original Breast CFR funding beginning in 1995, and therefore mutation testing was performed through multiple funding sources including NCI (a supplement) using several methodologies. The majority of mutational analyses of *BRCA1* and *BRCA2* were undertaken by laboratories closely associated with the Breast CFRs and funded from local sources. A validation study was conducted for the methods used between 1997 and 2000, including two-dimensional gel (2-D gel) scanning, denaturing high performance liquid chromatography (DHPLC), enzymatic mutation detection (EMD) and protein truncation tests (PTT) [3]. Specificity and sensitivity of the methods for protein-truncating mutations were comparable to genomic sequencing of all the coding exons in *BRCA1* and *BRCA2*. An additional method EGAN, based on Conformation Specific Gel Electrophoresis (CSGE) [4,5] has been used for testing of the California samples. EGAN has been validated on a blinded patient set and compared favorably to full sequence analysis results in the same patients (sensitivity of 97.4% in detecting *BRCA1* and *BRCA2* sequence changes) (A. Miron, pers. comm.).

More recently, a substantial proportion of testing, funded by NIH, has been performed by Myriad Genetic Laboratories, Inc., using full sequence analysis (BRC-Analysis) (this was prior to their introduction of testing for large genomic re-arrangements, deletions, and insertions) [6]. The mutation detection method and number of probands tested at each registry are shown in Table 1, excluding those tested for only the three Ashkenazi Jewish mutations. Women recruited because of their Ashkenazi Jewish heritage were screened for the three founder mutations, 185delAG and 5382insC in *BRCA1* and 6174delT in *BRCA2*, primarily funded through a supplement from the NIH. For the population-based families, the proband was tested. For the clinic-based families, the proband was tested if she was affected with breast cancer, else the youngest breast cancer case in the family from whom a blood sample was available was tested. For the purposes of this report, the affected individual tested will be referred to as the proband. In families in which a deleterious mutation was identified, participating family members for whom we had collected blood were tested when warranted for the same mutation. At the Philadelphia and Utah Breast CFRs, family members were only tested after consenting specifically to genetic testing and counseling. In the Australian Breast CFR, the process for and uptake to the offer of genetic test results has been reported previously [7].

Definition of deleterious mutations

The criteria for defining deleterious mutations were those used by the Breast Information Core (BIC; <http://research.nhgri.nih.gov/bic/>) and Myriad Genetic Laboratories, Inc. For *BRCA1*, any frameshift or nonsense mutation that occurs at or before codon 1,853 was classified as deleterious. For *BRCA2*, any frameshift or nonsense mutation that occurs at or before codon 3,309 was classified as deleterious. Missense changes at the cysteines and the histidine in the ring finger of *BRCA1* were considered deleterious, as well as the R1699W and A1708E substitutions [8]. Missense changes at the first methionine for both genes were also classified as deleterious.

Results

Mutation testing results for non-Ashkenazi Jewish pro-bands are shown in Table 1. For families tested for *BRCA1*, 5.1% (233/4,531) carried deleterious mutations. For families tested for *BRCA2*, 4.7% (193/4,084) carried deleterious mutations. Three probands were compound heterozygotes carrying deleterious mutations in both *BRCA1* and *BRCA2*. The frequencies of mutations identified from clinic-based families were 9.9% for *BRCA1* and 8.6% for *BRCA2*, and from the population-based families were 4.0% for *BRCA1* and 3.7% for *BRCA2*. Differences across registries may reflect the differences in sampling and extent and type of

testing across registries and between population-based and clinic-based sites. Testing of family members in carrier families identified an additional 259 *BRCA1* and 242 *BRCA2* carriers.

Of the 1,385 Ashkenazi Jewish probands tested for the three founder mutations, 241 (17.4%) carried a mutation (Table 2). Testing of DNA from available family members identified an additional 155 carriers, for a total of 430 female mutation carriers. Three women were found to be compound heterozygotes, carrying both a *BRCA1* 185delAG and *BRCA2* 6174delT mutation. These 1,385 probands were not included in Table 1 because they were tested only for the three Ashkenazi Jewish founder mutations.

The total number of female *BRCA1* and *BRCA2* mutation carriers, including probands and family members, was 1,360 (788 *BRCA1*, 566 *BRCA2*, and 6 with both *BRCA1* and *BRCA2* mutations) (Table 3). Of the total mutation carriers, 313 of the 788 (39.7%) of the *BRCA1* carriers, 235 of the 566 (41.5%) *BRCA2* carriers and 0 of 6 compound heterozygotes were unaffected with breast cancer at the time of testing. The age distribution of the female carriers by breast cancer status is shown in Table 4. In addition, 169 *BRCA1* and 114 *BRCA2* male mutation carriers have been identified.

The frequency of mutations was also examined by race/ethnicity, age at diagnosis of the proband, and family history of breast or ovarian cancer. The number of probands tested, defined by racial/ethnic group, is shown in Table 5. The majority of mutation carriers were non-Hispanic white ($n = 310$), reflecting the demographics of the Breast CFR as a whole. An additional 42 Latino and 31 African-American mutation carriers, as well as 47 carriers from other ethnic groups, have been identified. A detailed family history of breast and other cancers was collected for all families enrolled in the Breast CFR. The vast majority of mutations were identified in probands who had a first-or second-degree relative with breast or ovarian cancer (Table 6). Probands with at least one first-degree relative diagnosed with breast cancer before age 50 years had the highest frequency of mutations at 12.7% for *BRCA1* and 8.2% for *BRCA2* (Table 6). For those without a family history of breast cancer, the frequency of mutations identified was 2.4% for *BRCA1* and 2.2% for *BRCA2*. Of the mutations identified, there were 132 and 156 distinct mutations in *BRCA1* and *BRCA2*, respectively.

The frequencies of each type of deleterious mutation were: 54.1% frameshift, 24.8% nonsense, 12.8% intervening sequence (IVS)/splice, and 7.5% missense for *BRCA1*; and 66.7% frameshift, 23.7% nonsense, 7.7% IVS/ splice, 0.6% missense, and 1.3% in-frame insertions/deletions (in-frame indel) for *BRCA2* (Fig 1). The 10 most frequently identified *BRCA1* and *BRCA2* mutations are shown in Fig 2. Reflecting the relatively high proportion of Ashkenazi Jewish families tested, the two Ashkenazi founder mutations were the most commonly found mutations in *BRCA1*. The distribution of distinct mutation types along the three coding segments of *BRCA1* (Exons 1–10; 21.1%, Exon 11; 53.4% and Exons 12–24; 25.6%) and *BRCA2* (Exons 1–10; 23.1%, Exon 11; 50.0% and Exons 12–27; 26.9%) were similar between the two genes.

Discussion

Overall, we have found deleterious mutations in approximately 10% of families screened to date for mutations in *BRCA1* and *BRCA2*, with similar percentages for each gene. The frequency of deleterious mutations identified in clinic-based families was two-fold (18.5%) of that identified in the population-based families (9.4%). The higher frequency of mutations may be due to several possibilities. First, based on the nature of the recruitment, the clinic-based families have a stronger family history than the population-based families, and as such have a higher likelihood of carrying mutations. Second, a proportion of the clinic-based families were known to have a deleterious mutation at enrollment. In particular, approximately 41% of

families from the Utah Breast CFR carry deleterious mutations, largely due to referral of families from a research study in which mutations had already been identified in the families. The frequency for the population-based families may be higher than for breast cancer cases in general due to the fact that the three population-based sites of the Breast CFR over-sampled for younger ages at diagnosis, as well as for family history in Ontario and California.

Of the Breast CFR Ashkenazi families screened for only the three founder mutations, 17.9% carried one of the mutations. This is similar to what was observed by Myriad Genetic Laboratories Inc., who found 20.4% of tested individuals of Ashkenazi Jewish ancestry carried deleterious mutations [6]. In the same report, of 10,000 individuals screened for mutations, deleterious mutations were identified for 17.2% of those screened [6]. The frequency of mutations for individuals screened by Myriad Genetic Laboratories Inc. is higher than for our population-based families, likely reflecting that those screened were clinical samples sent for screening because they had a high prior probability of carrying deleterious mutations in *BRCA1* and *BRCA2*.

The distributions of detected *BRCA1* and *BRCA2* mutations across the genes were similar to what has been reported in the Breast Information Core (BIC) database. For both genes, approximately half the mutations were detected in exon 11 (which constitutes approximately 60% of the coding regions of each gene). The most common type of clinically significant *BRCA1* and *BRCA2* mutations in the Breast CFR were frameshift mutations (54.9%) followed by nonsense alterations (24.8%). Missense and IVS/splice variants were found less frequently, whereas in-frame mutations were infrequent. For testing performed by cDNA based PTT and 5' sequencing (as described in [3]), it is possible that some deleterious in-frame deletions that did not cause detectable protein shortening and some missense mutations that were not contained in the 5' region would have been missed. Furthermore, none of the testing methods used detect large rearrangements/insertions/deletions that have been estimated to account for approximately 12% of mutations in *BRCA1* and *BRCA2* [9]. We had previously reported that in a population-based sample of multiple-case families from the Australian Breast CFR ($n = 66$), 2 of 10 *BRCA1* mutations were large deletions that involved the promoter region of *BRCA1* (large genomic alterations that lie outside the promoter region and *BRCA2* were not studied) [10]. Therefore, it is likely that a small proportion of mutations have not yet been identified in these probands. There is an on-going study to test for large insertions/deletions in *BRCA1* and *BRCA2* in a set of cases selected for family history and breast cancer pathology.

Although the number of unclassified variants (UCVs), including missense and splice variants, identified in the Breast CFR sample is large (data not presented), only a small fraction have so far been shown to be functionally deleterious and thus potentially of clinical significance. Methods to evaluate *BRCA1* and *BRCA2* UCVs to classify them as deleterious or likely neutral have been published [8,11–14]. These methods are being applied to the Breast CFR unclassified variants and classifications are being entered into the Breast CFR database.

Nearly 6,000 probands in the Breast CFR were tested for mutations in *BRCA1* and *BRCA2*. More than 1,300 *BRCA1* and *BRCA2* mutation carriers have been identified in a total of 671 carrier families, including six compound heterozygotes. Mutation testing of probands for families not yet tested, and the application of new mutation testing strategies [e.g., multiplex ligation-dependent probe amplification (MLPA) from MRC-Holland) and regulatory region screening] is ongoing. Once mutations are identified in probands, additional family members for whom DNA samples are available, are tested for the family mutation.

To date, the Breast CFR data on *BRCA1* and *BRCA2* mutation status have been used to estimate the populationbased prevalence of *BRCA1* mutations [15–18], the investigation of lifestyle factors [19–21]; and genetic factors [22,23] that might modify the risk of breast cancer for

BRCA1 and *BRCA2* mutation carriers, and risk of breast and ovarian cancer for relatives of cancer patients with and without *BRCA1* or *BRCA2* mutations [24].

In conclusion, the value of the Breast CFR resource has been greatly enhanced by the testing for germline *BRCA1* and *BRCA2* mutations in probands and in many family members of identified carriers. These data, in combination with the family history, epidemiology, pathology, and follow-up data will facilitate studies of penetrance, genotype–phenotype correlations, gene–gene and gene–environment interactions, modifiers of risk in carriers, risks associated with unclassified variants or polymorphisms, and outcomes, as well as studies of characteristics of *BRCA1*- and *BRCA2*-associated tumors and assist in the efforts to discover novel breast cancer susceptibility genes. The Breast CFR resource is available to all researchers for collaborative, interdisciplinary, and translational studies of the genetic epidemiology of breast cancer. Detailed information on how to access the resource can be found at the URL: <http://epi.grants.cancer.gov/CFR/>, as well as citations of publications resulting from use of the Breast CFR. The resource will continue to be strengthened by additional knowledge of *BRCA1* and *BRCA2* mutation status and continual follow-up of all families.

Acknowledgments

This work was supported by the National Cancer Institute, National Institutes of Health under RFA # CA-95-011 and through cooperative agreements with members of the Breast Cancer Family Registry and Principal Investigators, including Cancer Care Ontario (U01 CA69467), Columbia University (U01 CA69398), Fox Chase Cancer Center (U01 CA69631), Huntsman Cancer Institute (U01 CA69446), Huntsman Cancer Institute (U01 CA69446), Northern California Cancer Center (U01 CA69417), University of Melbourne (U01 CA69638), and Research Triangle Institute Informatics Support Center (RFP No. N02PC45022-46). Mutation testing in Australia was supported by grants from the National Health and Medical Research Council (NHMRC) and the Victorian Breast Cancer Research Consortium (VBCRC). Mutation testing at Fox Chase Cancer Center was in part supported by an Ovarian Cancer SPORE grant (P50 CA83638). Mutation testing in Ontario was supported in part by Cancer Care Ontario. We wish to thank members of the Ontario Cancer Genetics Network for their contributions to the study. MCS is a Senior Research Fellow of the NHMRC and JLH is an Australia Fellow and a VBCRC Group Leader. The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centers in the Breast CFR, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government or the Breast CFR.

References

1. John EM, Hopper JL, Beck JC, et al. The Breast Cancer Family Registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer. *Breast Cancer Res* 2004;6:R375–R389. [PubMed: 15217505]doi:10.1186/bcr801
2. Apicella C, Peacock SJ, Andrews L, et al. Determinants of preferences for genetic counselling in Jewish women. *Fam Cancer* 2006;5:159–167. [PubMed: 16736286]doi:10.1007/s10689-005-3871-7
3. Andrulis IL, Anton-Culver H, Beck J, et al. Comparison of DNA- and RNA-based methods for detection of truncating *BRCA1* mutations. *Hum Mutat* 2002;20:65–73. [PubMed: 12112659]doi:10.1002/humu.10097
4. Ganguly A, Rock MJ, Prockop DJ. Conformation-sensitive gel electrophoresis for rapid detection of single-base differences in double-stranded PCR products and DNA fragments: evidence for solvent-induced bends in DNA heteroduplexes. *Proc Natl Acad Sci USA* 1993;90:10325–10329. [PubMed: 8234293]doi:10.1073/pnas.90.21.10325
5. Korkko J, Annunen S, Pihlajamaa T, et al. Conformation sensitive gel electrophoresis for simple and accurate detection of mutations: comparison with denaturing gradient gel electrophoresis and nucleotide sequencing. *Proc Natl Acad Sci USA* 1998;95:1681–1685. [PubMed: 9465076]doi:10.1073/pnas.95.4.1681
6. Frank TS, Deffenbaugh AM, Reid JE, et al. Clinical characteristics of individuals with germline mutations in *BRCA1* and *BRCA2*: analysis of 10,000 individuals. *J Clin Oncol* 2002;20:1480–1490. [PubMed: 11896095]doi:10.1200/JCO.20.6.1480

7. Keogh LA, Southey MC, Maskiell J, et al. Uptake of offer to receive genetic information about BRCA1 and BRCA2 mutations in an Australian population-based study. *Cancer Epidemiol Biomarkers Prev* 2004;13:2258–2263. [PubMed: 15598789]
8. Goldgar DE, Easton DF, Deffenbaugh AM, et al. Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2. *Am J Hum Genet* 2004;75:535–544. [PubMed: 15290653]doi:10.1086/424388
9. Walsh T, Casadei S, Coats KH, et al. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. *JAMA* 2006;295:1379–1388. [PubMed: 16551709] doi:10.1001/jama.295.12.1379
10. Smith LD, Tesoriero AA, Ramus SJ, et al. BRCA1 promoter deletions in young women with breast cancer and a strong family history: a population-based study. *Eur J Cancer* 2007;43:823–827. [PubMed: 17317153]doi:10.1016/j.ejca.2007.01.011
11. Tavtigian SV, Deffenbaugh AM, Yin L, et al. Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral. *J Med Genet* 2006;43:295–305. [PubMed: 16014699]doi:10.1136/jmg.2005.033878
12. Chen X, Truong TT, Weaver J, et al. Intronic alterations in BRCA1 and BRCA2: effect on mRNA splicing fidelity and expression. *Hum Mutat* 2006;27:427–435. [PubMed: 16619214] doi:10.1002/humu.20319
13. Abkevich V, Zharkikh A, Deffenbaugh AM, et al. Analysis of missense variation in human BRCA1 in the context of inter-specific sequence variation. *J Med Genet* 2004;41:492–507. [PubMed: 15235020]doi:10.1136/jmg.2003.015867
14. Easton DF, Deffenbaugh AM, Pruss D, et al. A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. *Am J Hum Genet* 2007;81:873–883. [PubMed: 17924331]doi:10.1086/521032
15. Ozelik H, Knight JA, Glendon G, et al. Individual and family characteristics associated with protein truncating BRCA1 and BRCA2 mutations in an Ontario population based series from the Cooperative Family Registry for Breast Cancer Studies. *J Med Genet* 2003;40:e91. [PubMed: 12920083] doi:10.1136/jmg.40.8.e91
16. Southey MC, Tesoriero AA, Andersen CR, et al. BRCA1 mutations and other sequence variants in a population-based sample of Australian women with breast cancer. *Br J Cancer* 1999;79:34–39. [PubMed: 10408690]doi:10.1038/sj.bjc.6690008
17. John EM, Miron A, Gong G, et al. Prevalence of pathogenic BRCA1 mutation carriers in 5 US racial/ethnic groups. *JAMA* 2007;298:2869–2876. [PubMed: 18159056]doi:10.1001/jama.298.24.2869
18. Whittemore AS, Gong G, John EM, et al. Prevalence of BRCA1 mutation carriers among U.S. non-Hispanic Whites. *Cancer Epidemiol Biomarkers Prev* 2004;13:2078–2083. [PubMed: 15598764]
19. Haile RW, Thomas DC, McGuire V, et al. BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50. *Cancer Epidemiol Biomarkers Prev* 2006;15:1863–1870. [PubMed: 17021353]doi:10.1158/1055-9965.EPI-06-0258
20. McGuire V, John EM, Felberg A, et al. No increased risk of breast cancer associated with alcohol consumption among carriers of BRCA1 and BRCA2 mutations ages <50 years. *Cancer Epidemiol Biomarkers Prev* 2006;15:1565–1567. [PubMed: 16896052]doi:10.1158/1055-9965.EPI-06-0323
21. Breast Cancer Family Registry, Kathleen Cunningham Consortium for Research into Familial Breast Cancer (Australasia), Ontario Cancer Genetics Network (Canada). Smoking and risk of breast cancer in carriers of mutations in BRCA1 or BRCA2 aged less than 50 years. *Breast Cancer Res Treat* 2007;109:67–75. [PubMed: 17972172]
22. Antoniou AC, Sinilnikova OM, Simard J, et al. RAD51 135G→C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. *Am J Hum Genet* 2007;81:1186–1200. [PubMed: 17999359]doi:10.1086/522611
23. Couch FJ, Sinilnikova O, Vierkant RA, et al. AURKA F3II polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 study. *Cancer Epidemiol Biomarkers Prev* 2007;16:1416–1421. [PubMed: 17627006] doi:10.1158/1055-9965.EPI-07-0129

24. Lee JS, John EM, McGuire V, et al. Breast and ovarian cancer in relatives of cancer patients, with and without BRCA mutations. *Cancer Epidemiol Biomarkers Prev* 2006;15:359–363. [PubMed: 16492929]doi:10.1158/1055-9965.EPI-05-0687

Fig. 1.

The frequency of deleterious germline mutation types in *BRCA1* and *BRCA2* observed in the Breast CFR. In-frame indel refers to either insertions or deletions of nucleotides in multiples of three

Fig. 2.
The most common germline *BRCA1* and *BRCA2* mutations observed in the Breast CFR

Table 1

BRCA1 and *BRCA2* germline mutation testing for population-based and clinic-based families, excluding those tested for only the Ashkenazi Jewish founder mutations

Testing method Family registry	<i>BRCA1</i>		<i>BRCA2</i>		<i>BRCA1</i> and <i>BRCA2</i>	
	# Probands tested	# w/Deleterious mutations	Total # Carriers ^a	# Probands tested	# w/Deleterious mutations	Total # Carriers ^a
<i>Population-based</i>						
Australia	3,682	149		3,242	121	
Sequencing	724	31	47	429	16	481
2-D Gel	140	16		205	11	
PTT	501	10			0	
Ontario	83	5		224	5	
Sequencing	1,229	67	100	1,219	58	841
PTT	150	6		150	6	
N. California	1,062	51		1,060	48	
Heteroduplex	17	10		9	4	
Sequencing	1,729	51	68	1,594	47	801
2-D gel	34	2		411	13	
Heteroduplex	862	29		0	0	
Clinic-based—sequencing	833	20		1,183	34	
Philadelphia	849	84		842	72	
New York	241	19	29	236	15	29
Utah	438	30	42	438	27	49
Total	170	35	206	168	30	145
	4,531	233 (5.2%)	492	4,084	193 (4.7%)	4353

^a Includes tested family members

Table 2

Ashkenazi Jewish family testing for the three founder mutations

Family registry	# Probands# tested	Carrying <i>BRCA1</i> 185delAG		# Carrying <i>BRCA1</i> 5382insC carriers		# Carrying <i>BRCA2</i> 6174delT		# Carrying both <i>BRCA1</i> and <i>BRCA2</i>		Total # carrying mutations in any of the three founder mutations	
		Families	Individuals	Families	Individuals	Families	Individuals	Individuals	Individuals	Families	Individuals
Australia	319	17	18	7	26	24	350	350	48	79	79
New York	521	54	77	24	41	26	441	441	104	163	163
California	32	1	1	0	0	1	10	10	2	2	2
Ontario	361	34	45	8	16	13	250	250	55	87	87
Philadelphia	131	15	53	5	15	7	252	252	27	94	94
Utah	11	2	4	0	0	1	10	10	3	5	5
Totals	1,385	123 (8.9%)	198	44 (3.2%)	98	72 (5.2%)	1313	1313	241 (17.4%)	430	430

Table 3

Total numbers of *BRCA1* and *BRCA2* germline mutation carriers, including those tested for only the Ashkenazi Jewish founder mutations

	Families	Individuals
<i>BRCA1</i> mutation carriers	400	788
<i>BRCA2</i> mutation carriers	265	566
<i>BRCA1</i> and <i>BRCA2</i> mutation carriers	6	6
Total number	671	1,360

Table 4
Distribution of affected and unaffected female mutation carriers by age and germline *BRCA1* and *BRCA2* mutation status^a

Affected status (breast cancer)	Age in years at diagnosis for cases and age at interview for unaffected				UnknownTotal
	<30	30–39	40–49	50–59	60+
<i>BRCA1</i>					
Affected	43	193	16851		19
Unaffected	69	75	7141		18
<i>BRCA2</i>					
Affected	21	107	11065		28
Unaffected	43	56	4840		23
					1475
					39313
					0331
					25235

^aExcluding the 6 compound heterozygotes

Table 5

BRCA1 and *BRCA2* germline mutation testing by race/ethnicity, excluding those tested only for the Ashkenazi Jewish founder mutations

Race/Ethnicity	<i>BRCA1</i> testing		<i>BRCA2</i> testing	
	# Probands tested	# w/Mutations	# Probands tested	# w/Mutations
Non-Hispanic white	2,875	172	2,499	138
Hispanic	532	24	520	18
African American	410	14	405	17
Asian/Pacific Islander	525	5	503	13
Other/multiple race	133	11	125	6
Unknown	56	7	32	1
Total	4,531	233	4,084	193

Table 6

BRCA1 and *BRCA2* germline mutation testing by family history of breast and ovarian cancer, excluding those tested for only the Ashkenazi founder mutations

Family history of breast or ovarian cancer	<i>BRCA1</i>		<i>BRCA2</i>	
	# Probands tested	# w/Mutations (%)	# Probands tested	# w/Mutations (%)
No family history in 1st or 2nd degree relatives	1,592	38 (2.4)	1,343	30 (2.2)
Unknown/No relatives	126	9 (7.1)	107	8 (7.5)
With family history in a relative				
Breast cancer at age <50 years in at least one 1st degree family relative	856	109 (12.7)	821	67 (8.2)
Breast cancer at age ≥50 years in at least one 1st degree family relative	994	28 (2.8)	923	41 (4.4)
Breast cancer at age <50 years in a 2nd degree relative (no 1st degree relative affected)	309	20 (6.5)	285	19 (6.7)
Breast cancer at age ≥50 years in a 2nd degree relative (no 1st degree relative affected)	535	23 (4.3)	482	26 (5.4)
Ovarian cancer only in any relative	119	6 (5.0)	123	2 (1.6)
Total	4,531	233 (5.1)	4,084	193 (4.7)